AIM: To investigate the clinical performances of rapidstool test (ImmunoCard STAT HpSA, Meridian DiagnosticInc.) in the evaluation of eradication therapy of H pyloriand to compare it with a well-known and validatedlab...AIM: To investigate the clinical performances of rapidstool test (ImmunoCard STAT HpSA, Meridian DiagnosticInc.) in the evaluation of eradication therapy of H pyloriand to compare it with a well-known and validatedlaboratory stool test (Amplified IDEA Hp StAR, Dako).METHODS: Stool samples of 122 patients wereevaluated after eradication therapy of H pylori. H pyloristatus was assessed by 13C-urea breath test (UBT).Stool specimens were tested using either the rapidimmunoassay kit or the laboratory immunoassay kit.RESULTS: Forty-three patients were infected and 79non-infected. Sensitivity and specificity of ImmunoCardSTAT and Hp StAR were 58.14% and 76.4%, and97.47% and 98.73%, respectively (P > 0.05). Overallagreement between the two tests was 92.6% (113 of122 cases).CONCLUSION: ImmunoCard STAT seems to haverather low performances, and it cannot be regarded as areliable tool in the post-treatment setting. Also Hp StARcannot be recommended to confirm H pylori eradicationafter treatment.展开更多
文摘AIM: To investigate the clinical performances of rapidstool test (ImmunoCard STAT HpSA, Meridian DiagnosticInc.) in the evaluation of eradication therapy of H pyloriand to compare it with a well-known and validatedlaboratory stool test (Amplified IDEA Hp StAR, Dako).METHODS: Stool samples of 122 patients wereevaluated after eradication therapy of H pylori. H pyloristatus was assessed by 13C-urea breath test (UBT).Stool specimens were tested using either the rapidimmunoassay kit or the laboratory immunoassay kit.RESULTS: Forty-three patients were infected and 79non-infected. Sensitivity and specificity of ImmunoCardSTAT and Hp StAR were 58.14% and 76.4%, and97.47% and 98.73%, respectively (P > 0.05). Overallagreement between the two tests was 92.6% (113 of122 cases).CONCLUSION: ImmunoCard STAT seems to haverather low performances, and it cannot be regarded as areliable tool in the post-treatment setting. Also Hp StARcannot be recommended to confirm H pylori eradicationafter treatment.
